SAIC-SAI-SAFIS 2020

VALENTINA SCARDIGNO; MÓNICA H. VAZQUEZ-LEVIN; MARÍA VICTORIA MENCUCCI

Congreso; Reunión Anual de Sociedades de Biociencia. SAIC-SAI-SAFIS 2020; 2020

Aim: Bladder cancer (BC) is one of the ten solid tumors with highest incidence/mortality worldwide. Clinically, it is classified as non-muscle-invasive (NMIBC; Ta-T1 stages) and muscle-invasive (MIBC; T2-T4 stages). Samples are also classified by tumor grade (G1 to G3, G3 most aggressive). BC molecular classification has also been reported. In a murine model of BC progression/aggressiveness, we reported β-catenin nuclear translocation, higher expression of Ephrin B1 (EFNB1) ligand and its EphB2 (EPHB2) receptor, and STAT3-related pathway activation. Also, increased expression of EFNB1 protein was shown in BC patients (Mencucci et al, 2020). This study aimed to further characterize EFNB1 and EPHB2 expression in BC.M&M: Datasets were queried to analyze EFNB1 and EPHB2 mRNA levels in BC patients (GSE13507, GSE32894). To explore binding sites of TCF4 transcription factor to EFNB1 and EPHB2 promoters, a set of programs were used (Ensembl, Methyl Primer Express v1.0, PROMO).Results: EFNB1 mRNA levels were higher in tumor samples (n=165) than in mucosa surrounding cancer (n=58); Ta and T1, and G1 tumors had higher expression levels than controls (p